Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00814931 · ClinicalTrials.gov registry record · Phase 1

Examining the Effects of CXB722 in Neuroendocrine Stress Response in Healthy Males

A Phase 1 study, sponsored by CeNeRx BioPharma.

Completed
Registry status
Phase 1
Development phase
23
Enrollment target

NCT00814931 is a Phase 1 study that has completed, run by CeNeRx BioPharma. The registered enrollment target is 23 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00814931, a Phase 1 study, has completed, sponsored by CeNeRx BioPharma.

COMPLETED
Registry status
Phase 1
Development phase
23 participants
Enrollment target

Study Summary

The purpose of this study is to assess the effects of CXB722 on neuroendocrine stress response and subjective reports related to mood and stress during and after experimentally induced stress among healthy young males.

Interventions

  • DRUG Placebo
  • DRUG CXB722

Trial Details

FieldValue
Enrollment Target 23 participants
Start Date 2008-12
Est. Completion 2008-12
Phase Phase 1

Sponsor

CeNeRx BioPharma

4 total trials

What the Registry Record Tells You About NCT00814931

The ClinicalTrials.gov registry entry for NCT00814931 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CeNeRx BioPharma, which has 4 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT00814931 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00814931 about?

NCT00814931 is a clinical study titled "Examining the Effects of CXB722 in Neuroendocrine Stress Response in Healthy Males". The purpose of this study is to assess the effects of CXB722 on neuroendocrine stress response and subjective reports related to mood and stress during and after experimentally induced stress among healthy young males.

What is the current status of trial NCT00814931?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2008-12. Estimated completion is 2008-12.

What interventions are being tested in trial NCT00814931?

The interventions under investigation include: Placebo (DRUG), CXB722 (DRUG).

Who is sponsoring clinical trial NCT00814931?

This trial is sponsored by CeNeRx BioPharma, which has 4 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.